Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2022 July-August;88(7-8) > Minerva Anestesiologica 2022 July-August;88(7-8):544-53

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Anestesiologica 2022 July-August;88(7-8):544-53

DOI: 10.23736/S0375-9393.22.16229-2

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Buprenorphine versus dexamethasone as perineural adjuvants in femoral and adductor canal nerve blocks for total knee arthroplasty: a randomized, non-inferiority clinical trial

José R. ORTIZ-GÓMEZ 1 , Marta PEREPÉREZ-CANDEL 1, Óscar MARTÍNEZ-GARCÍA 1, Inocencia FORNET-RUIZ 2, Andrea ORTIZ-DOMÍNGUEZ 3, Francisco J. PALACIO-ABIZANDA 4, Ana ROYUELA 5, José M. VÁZQUEZ-TORRES 1, José M. RODRÍGUEZ-DEL-RÍO 1

1 Department of Anesthesiology, University Hospital of Navarre, Pamplona, Spain; 2 Department of Anesthesiology, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain; 3 School of Medicine, University of Navarre, Pamplona, Spain; 4 Department of Anesthesiology, University Hospital Gregorio Marañón, Madrid, Spain; 5 Unit of Biostatistics, Puerta de Hierro-Segovia de Arana Health Research Institute, CIBER Epidemiology and Public Health, Madrid, Spain



BACKGROUND: Optimal control of acute postoperative pain and prevention of chronic persistent pain in total knee arthroplasty (TKA) remain a challenge.
METHODS: A randomized, non-inferiority clinical trial (385 patients) evaluated every hour immediate postoperative pain during 24 h, using a verbal rating 11-point scale for patient self-reporting of pain (VRS11). All patients received subarachnoid anesthesia and were randomly allocated in four groups: single shots femoral (FNB) or adductor canal blocks (ACB), both with dexamethasone (dex) and buprenorphine (bup). Patients received intravenous analgesia (metamizole magnesium, dexketoprofen) and rescue analgesia when needed: intravenous (paracetamol and morphine) and/or regional (femoral and sciatic nerve blocks). Demographics and adverse effects were also recorded.
RESULTS: A 45.7% of patients had pain: bupACB 56.3%, bupFNB 50.0%, dexACB 40.6% and dexFNB 36.1% (P=0.022). Rescue analgesia was needed in 37.7% of patients (P=0.128). There were statistical differences in percentage of timepoints without pain (95.0±7.9%, P=0.014) and mean VRS11 (0.18±0.3, P=0.012) but no differences in distribution of intensity periods of pain. There were no significant differences in the need of rescue analgesia excepting the use of intravenous morphine (P=0.025).
CONCLUSIONS: Buprenorphine is in the present trial inferior to dexamethasone by less than the established non-inferiority limit when used as perineural adjuvant in femoral nerve or adductor canal blocks in total knee arthroplasty analgesia. So, it could be considered an alternative in patients where dexamethasone is contraindicated, such as diabetics.


KEY WORDS: Pain, postoperative; Arthroplasty, replacement, knee; Nerve block; Dexamethasone; Buprenorphine

top of page